Recent data on the role for angiogenesis in rheumatoid arthritis

被引:83
作者
Clavel, G
Bessis, N
Boissier, MC
机构
[1] CHU Nord, Serv Rhumatol, F-80054 Amiens 1, France
[2] Univ Paris 13, UFR Leonard de Vinci, UPRES EA 3408, Grp Rech Immunopathol, F-93430 Paris, France
[3] Hop Avicenne, AP HP, Serv Rhumatol, F-93009 Bobigny, France
关键词
angiogenesis; rheumatoid arthritis; VEGF; angiopoietin-1;
D O I
10.1016/S1297-319X(03)00088-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiogenesis is central to the development and perpetuation of rheumatoid synovitis. Vascular endothelial growth factor (VEGF), the main mediator of angiogenesis, is found in the synovial fluid and serum of patients with rheumatoid arthritis (RA), and its expression is correlated with disease severity. Compelling evidence that VEGF is involved in synovitis has been obtained from experimental models of RA. In particular, VEGF inhibition by synthetic compounds (e.g. TNP-470) or by naturally occurring factors (e.g., the soluble VEGF receptor) produce therapeutic effects. Angiopoietin-1, a recently discovered growth factor specific for neovascularization, is expressed within the rheumatoid synovium and may be stimulated by TNF-alpha. Other compounds, including integrins, fibroblast growth factor, and proinflammatory cytokines contribute to joint angiogenesis and, therefore, to the development of rheumatoid synovitis. Assessing vascularity may prove useful for evaluating or even predicting bone destruction. Furthermore, inhibition of angiogenesis may prove useful as an adjunct to current anti-inflammatory treatments. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:321 / 326
页数:6
相关论文
共 60 条
  • [1] Ballara S, 2001, ARTHRITIS RHEUM, V44, P2055, DOI 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO
  • [2] 2-2
  • [3] Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts
    Cho, ML
    Cho, CS
    Min, SY
    Kim, SH
    Lee, SS
    Kim, WU
    Min, DJ
    Min, JK
    Youn, JH
    Hwang, SY
    Park, SH
    Kim, HY
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (05): : 1202 - 1209
  • [4] COXON A, 2002, ANN RHEUM DIS S1, V61, P263
  • [5] de Bandt M, 2000, ARTHRITIS RHEUM, V43, P2056
  • [6] VASCULAR-PERMEABILITY FACTOR ENDOTHELIAL GROWTH-FACTOR (VPF/VEGF) - ACCUMULATION AND EXPRESSION IN HUMAN SYNOVIAL-FLUIDS AND RHEUMATOID SYNOVIAL TISSUE
    FAVA, RA
    OLSEN, NJ
    SPENCERGREEN, G
    YEO, KT
    YEO, TK
    BERSE, B
    JACKMAN, RW
    SENGER, DR
    DVORAK, HF
    BROWN, LF
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) : 341 - 346
  • [7] The biology of vascular endothelial growth factor
    Ferrara, N
    DavisSmyth, T
    [J]. ENDOCRINE REVIEWS, 1997, 18 (01) : 4 - 25
  • [8] MORPHOMETRIC ANALYSIS OF BLOOD-VESSELS IN SYNOVIAL MEMBRANES OBTAINED FROM CLINICALLY AFFECTED AND UNAFFECTED KNEE JOINTS OF PATIENTS WITH RHEUMATOID-ARTHRITIS
    FITZGERALD, O
    SODEN, M
    YANNI, G
    ROBINSON, R
    BRESNIHAN, B
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1991, 50 (11) : 792 - 796
  • [9] GALE N, 1999, GENE DEV, V1310, P55
  • [10] Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature
    Gerlag, DM
    Borges, E
    Tak, PP
    Ellerby, HM
    Bredesen, DE
    Pasqualini, R
    Ruoslahti, E
    Firestein, GS
    [J]. ARTHRITIS RESEARCH, 2001, 3 (06) : 357 - 361